Last Updated: June 17, 2026

sodium nitrite - Profile


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for sodium nitrite and what is the scope of freedom to operate?

Sodium nitrite is the generic ingredient in two branded drugs marketed by Hope Pharms and is included in two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sodium nitrite has thirty patent family members in fifteen countries.

Summary for sodium nitrite
International Patents:30
US Patents:8
Tradenames:2
Applicants:1
NDAs:2
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for sodium nitrite
Generic Entry Date for sodium nitrite*:
Constraining patent/regulatory exclusivity:
Dosage:

SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for sodium nitrite

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hope Pharms SODIUM NITRITE sodium nitrite SOLUTION;INTRAVENOUS 203922-001 Feb 14, 2012 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Hope Pharms SODIUM NITRITE sodium nitrite SOLUTION;INTRAVENOUS 203922-001 Feb 14, 2012 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Hope Pharms NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444-001 Jan 14, 2011 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Hope Pharms NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444-001 Jan 14, 2011 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Hope Pharms NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444-001 Jan 14, 2011 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Hope Pharms NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444-001 Jan 14, 2011 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Hope Pharms NITHIODOTE sodium nitrite; sodium thiosulfate SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS 201444-001 Jan 14, 2011 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for sodium nitrite

Country Patent Number Title Estimated Expiration
Spain 2880500 ⤷  Start Trial
Cyprus 1121939 ⤷  Start Trial
Japan 2012517474 亜硝酸ナトリウムを含む医薬組成物 ⤷  Start Trial
San Marino T201900476 ⤷  Start Trial
Croatia P20191516 ⤷  Start Trial
Australia 2010213743 Sodium nitrite-containing pharmaceutical compositions ⤷  Start Trial
Japan 2015199764 亜硝酸ナトリウムを含む医薬組成物 (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for sodium nitrite

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2666774 CA 2020 00037 Denmark ⤷  Start Trial PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217
0290047 SPC/GB97/078 United Kingdom ⤷  Start Trial PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
1856135 LUC00153 Luxembourg ⤷  Start Trial PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113
2822954 1890030-8 Sweden ⤷  Start Trial PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625
2932970 SPC/GB18/041 United Kingdom ⤷  Start Trial PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518
2673237 201940014 Slovenia ⤷  Start Trial PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1173; DATE OF NATIONAL AUTHORISATION: 20180322; AUTHORITY FOR NATIONAL AUTHORISATION: EU
1758590 LUC00029 Luxembourg ⤷  Start Trial PRODUCT NAME: SEL DE SODIUM D'ACIDE DEOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: IS/1/16/071/01 20170401
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Investment Scenario and Fundamentals Analysis for Sodium Nitrite

Last updated: February 20, 2026

What is the Market for Sodium Nitrite?

Sodium nitrite (NaNO₂) is a chemical used primarily as a food additive, preservative in cured meats, and in pharmaceutical applications. It is also an intermediary in chemical synthesis and a corrosion inhibitor in industrial processes. The global demand for sodium nitrite is driven by its roles in food preservation, industrial applications, and emerging pharmaceutical uses.

The global sodium nitrite market was valued at approximately USD 245 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of roughly 4.2% through 2027, reaching USD 300 million. Growth drivers include increasing demand for processed foods, expansion of industrial applications, and regulatory approvals for new pharmaceutical indications.

What Are the Key Market Drivers and Barriers?

Drivers:

  • Food industry expansion: Sodium nitrite's role in meat curing is critical, especially in developing regions experiencing rapid urbanization.
  • Industrial uses: Corrosion prevention and chemical synthesis industries rely on sodium nitrite.
  • Pharmaceutical development: Emerging use cases in targeted therapies, emergency medicine, and gasotransmitter research bolster future potential.

Barriers:

  • Regulatory restrictions: Stringent regulations on nitrogen compounds in food and medicine limit usage scope and scale.
  • Environmental concerns: Waste management and potential environmental impact pose risks, incurring costs or restrictions.
  • Market volatility: Price fluctuations driven by raw material costs (e.g., sodium compounds, nitric acid) impact profitability.

What Are the Core Fundamentals of Sodium Nitrite Production?

Raw Material Supply:

  • Sodium hydroxide, sodium nitrate, and nitric acid are primary inputs.
  • Raw material prices are sensitive to feedstock availability, energy costs, and geopolitical stability.

Manufacturing Processes:

  • Chemical oxidation: Sodium nitrate is reduced using sulfur dioxide or other reducing agents.
  • Electrochemical methods: Used primarily in high-purity applications, offering lower impurities.
  • Key players: Major chemical manufacturers include FMC Corporation, Fermion, and American Elements.

Cost Structure:

  • Raw materials account for approximately 60-70% of production costs.
  • Energy consumption and labor costs constitute the remaining share.
  • Typical production cost ranges from USD 0.70 to USD 1.10 per kilogram, depending on scale and process efficiency.

Regulatory & Quality Standards:

  • Food-grade sodium nitrite must meet standards set by FDA (U.S.), EFSA (Europe), and other authorities.
  • Pharmaceutical-grade products require compliance with cGMP (current Good Manufacturing Practice), adding complexity and costs.

What Are the Pharmacological and Emerging Applications?

Food Preservation:

  • Approved for use in processed meats for inhibiting bacterial growth.
  • Regulatory limits: Up to 200 ppm in the U.S. and EU.

Pharmaceutical Uses:

  • Investigational therapies: Role in NO (nitric oxide) donor systems for cardiovascular diseases.
  • Emergency medicine: Use in cyanide poisoning antidotes.
  • Research compounds: Explored as a precursor in gasotransmitter delivery systems.

Patent and Commercialization Outlook:

  • Limited current pharmaceutical patents specific to sodium nitrite.
  • Potential for new formulations or delivery mechanisms to extend lifecycle.

Who Are Key Industry Players?

Company Market Share Core Focus Notable Attributes
FMC Corporation High Chemical manufacturing Extensive global footprint, diversified product lines
Fermion Moderate Specialty chemicals, pharmaceuticals Focus on pharmaceutical-grade products
American Elements Niche Custom chemicals, nanomaterials Rapid custom synthesis, niche markets

What Are Investment Risks?

  • Regulatory tightening could restrict applications.
  • Raw material price volatility impacts margins.
  • Environmental liabilities increase with stricter regulations.
  • Market saturation in food applications limits growth potential.

How Does Sodium Nitrite Compare to Alternatives?

Alternative Application Advantages Disadvantages
Sodium erythorbate Food preservation Reduces nitrite amount needed Less effective as a curing agent
Nitrate compounds Food curing Longer shelf life Regulatory restrictions more stringent
Organic acids (e.g., lactic acid) Food preservation Natural appeal Limited efficacy in meat curing

Strategic Investment Considerations

  • Focus on specialty or pharmaceutical-grade supply chains.
  • Monitor regulatory developments, especially in food safety.
  • Consider vertical integration to control raw material costs.
  • Invest in R&D for novel applications in NO therapeutics or delivery mechanisms.

Key Takeaways

  • Market growth driven by food, industrial, and pharmaceutical sectors.
  • Production relies heavily on raw material costs and environmental compliance.
  • Regulatory landscape is a key risk factor with potential to restrict use.
  • Pharmaceutical applications present high-margin, innovation-driven opportunities.
  • Major players include FMC, Fermion, and American Elements, with niche opportunities for biotech collaborations.

FAQs

1. What are the main growth drivers for sodium nitrite?
The increase in processed meat consumption and industrial applications drive growth. Emerging pharmaceutical uses also contribute.

2. How sensitive is the market to raw material prices?
Very sensitive. Raw materials account for a significant portion of costs, with fluctuations impacting profitability.

3. What regulatory hurdles could affect sodium nitrite?
Food safety limits, environmental regulations, and pharmaceutical manufacturing standards pose potential restrictions.

4. Are there significant patent barriers in this market?
Generally low for bulk sodium nitrite, but proprietary formulations or delivery systems could provide patent opportunities.

5. What are the main risks associated with investing in sodium nitrite?
Regulatory restrictions, raw material price volatility, environmental liabilities, and market saturation in food applications.


References

[1] MarketWatch. (2023). Sodium Nitrite Market Forecasts. Retrieved from https://www.marketwatch.com/

[2] U.S. Food and Drug Administration (FDA). (2022). Food Additive Status List.

[3] European Food Safety Authority (EFSA). (2022). Chemical safety assessments.

[4] Grand View Research. (2022). Global Sodium Nitrite Market Size & Trends.

[5] Ritchie, J., & Wilson, L. (2020). Industrial Chemical Manufacturing Dynamics. Journal of Chemical Industry, 45(3), 150-165.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.